![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-adgif-27965.gif)
![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-ad-w33-mob-headergif-39012.gif)
Active Filter(s):
Details:
Balflu (favipiravir) is a RNA-directed RNA polymerase inhibitor, which is approved for the treatment of patients with mild to moderate Covid-19 Infection.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Balflu
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021